BeiGene, Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
255.77
+0.13 (0.05%)
May 2, 2025, 4:00 PM EDT - Market closed
BeiGene Revenue
In the year 2024, BeiGene had annual revenue of $3.81B with 54.96% growth. BeiGene had revenue of $1.19B in the quarter ending December 31, 2024, with 84.84% growth.
Revenue (ttm)
$3.81B
Revenue Growth
+54.96%
P/S Ratio
7.07
Revenue / Employee
$346,386
Employees
11,000
Market Cap
27.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
ONC News
- 5 days ago - U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire
- 17 days ago - BeiGene to Announce First Quarter 2025 Financial Results on May 7 - Business Wire
- 4 weeks ago - BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit - Benzinga
- 4 weeks ago - BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program - Business Wire
- 4 weeks ago - BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer - Business Wire
- 2 months ago - China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer - Benzinga
- 2 months ago - TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy - Business Wire
- 2 months ago - BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025 - Seeking Alpha